In the past week, PCRX stock has gone down by -3.67%, with a monthly decline of -30.40% and a quarterly plunge of -24.58%. The volatility ratio for the week is 5.46%, and the volatility levels for the last 30 days are 6.34% for Pacira BioSciences Inc The simple moving average for the past 20 days is -11.19% for PCRX’s stock, with a -29.86% simple moving average for the past 200 days.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
The price-to-earnings ratio for Pacira BioSciences Inc (NASDAQ: PCRX) is above average at 14.52x. The 36-month beta value for PCRX is also noteworthy at 0.87. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PCRX is 45.14M, and at present, short sellers hold a 14.92% of that float. The average trading volume of PCRX on July 24, 2024 was 1.07M shares.
PCRX) stock’s latest price update
Pacira BioSciences Inc (NASDAQ: PCRX) has seen a rise in its stock price by 1.20 in relation to its previous close of 19.98. However, the company has experienced a -3.67% decline in its stock price over the last five trading sessions. zacks.com reported 2024-07-17 that Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with Barclays repeating the rating for PCRX by listing it as a “Equal Weight.” The predicted price for PCRX in the upcoming period, according to Barclays is $25 based on the research report published on July 03, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $45, previously predicting the price at $80. The rating they have provided for PCRX stocks is “Overweight” according to the report published on March 07th, 2024.
Raymond James gave a rating of “Outperform” to PCRX, setting the target price at $42 in the report published on December 20th of the previous year.
PCRX Trading at -24.79% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.65% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 5.46%, as shares sank -28.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.80% lower at present.
During the last 5 trading sessions, PCRX fell by -3.00%, which changed the moving average for the period of 200-days by -29.94% in comparison to the 20-day moving average, which settled at $22.37. In addition, Pacira BioSciences Inc saw -40.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from SLONIN JONATHAN, who sale 2,836 shares at the price of $28.25 back on Jul 02 ’24. After this action, SLONIN JONATHAN now owns 95,557 shares of Pacira BioSciences Inc, valued at $80,117 using the latest closing price.
WILLIAMS KRISTEN, the Chief Administrative Officer of Pacira BioSciences Inc, sale 7,452 shares at $28.38 during a trade that took place back on Jun 13 ’24, which means that WILLIAMS KRISTEN is holding 102,912 shares at $211,488 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.69 for the gross margin
The net margin for Pacira BioSciences Inc stands at 0.1. The total capital return value is set at 0.07. Equity return is now at value 8.49, with 4.54 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at 0.35. The debt to equity ratio resting at 0.59. The interest coverage ratio of the stock is 7.59.
Currently, EBITDA for the company is 162.9 million with net debt to EBITDA at 2.44. When we switch over and look at the enterprise to sales, we see a ratio of 1.97. The receivables turnover for the company is 6.7for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In summary, Pacira BioSciences Inc (PCRX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
